Premium
Transcriptomic landscape of lenalidomide‐treated NK cells: Functional enhancement by down‐regulation of CD161
Author(s) -
Sim JeongMin,
Ahn JuWon,
Park YoungJoon,
Kim JongIl,
Kang SuJung,
Choi Seo-Hyeon,
Lee SeLin,
Hwang Min,
Cho JooYeon,
Lim Jaejoon,
Oh Soo-Yeon,
Kwack KyuBum
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.09284
Subject(s) - lenalidomide , downregulation and upregulation , cancer research , cytotoxicity , christian ministry , function (biology) , biology , in vitro , microbiology and biotechnology , immunology , multiple myeloma , gene , political science , biochemistry , law
Lenalidomide is a potential immunomodulator that enhances the anti‐tumor effect of natural killer (NK) cells. However, the underlying molecular mechanism of anti‐tumor effects and long‐term activating effect on NK cells are unclear. Here, we report that lenalidomide in the long stimulation with interleukin‐2 (IL‐2) enhances the proliferation and specific anti‐tumor function of NK cells by modulating transcriptomic patterns, including downregulation of KLRB1 (CD161). In conclusion, the results suggest that lenalidomide may be more applicable in the field of cancer immunotherapy by exhibiting specific cytotoxicity ability enhancement of NK cells against cancer cells as well as long‐term activating effect on NK cells. Support or Funding Information The research fund was supported by Ministry of Science, Technology and Information, Republic of Korea (Grant no. 2019R1F1A1054920)